---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-274258"
form_type: "8-K"
ticker: "CORT"
cik: "0001088856"
company_name: "CORCEPT THERAPEUTICS INC"
filed_at: "2026-06-17T20:36:46+00:00"
generated_at: "2026-06-17T20:38:46.398940+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Corcept resubmits NDA for relacorilant to FDA for Cushing's syndrome; six-month review expected

## Summary
- Resubmission based on pivotal GRACE trial and Phase III GRADIENT trial data.
- Includes additional analyses requested by FDA; expects six-month review cycle.
- Relacorilant shows durable symptom improvement without serious adverse events like hypokalemia or pregnancy termination.
- CEO states company looks forward to working with FDA toward approval.

## SEC filing metadata
- accession: 0001193125-26-274258
- form_type: 8-K
- ticker: CORT
- cik: 0001088856
- company_name: CORCEPT THERAPEUTICS INC
- filed_at: 2026-06-17T20:36:46+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1088856/000119312526274258/0001193125-26-274258-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1088856/000119312526274258/d159941d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-274258
- JSON: https://secwatch.observer/filing/0001193125-26-274258.json
- Plain text: https://secwatch.observer/filing/0001193125-26-274258.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.